37 3. Les freins à l'optimisation du traitement de l'insuffisance cardiaque en médecine générale ,
,
,
,
,
,
,
,
Prévalences et statut fonctionnel des cardiopathies ischémiques et de l'insuffisance cardiaque dans la population adulte en France: apports des enquêtes déclaratives «Handicap-Santé», Bull Epidémiol Hebd, vol.9, pp.172-181, 2014. ,
Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam Study, Eur Heart J, vol.25, issue.18, pp.1614-1619, 2004. ,
L'état de santé de la population en France, pp.250-253, 2017. ,
Mortalité après hospitalisation pour motif cardio-vasculaire. Direction de la Recherche, de Etudes, de l'Evaluation, des Statistiques, vol.21, 2017. ,
More 'malignant'than cancer? Five-year survival following a first admission for heart failure, Eur J Heart Fail, vol.3, issue.3, pp.315-322, 2001. ,
Repeated hospitalizations predict mortality in the community population with heart failure, Am Heart J, vol.154, issue.2, pp.260-266, 2007. ,
Une maladie chronique en augmentation alarmante, Soins. avr, vol.58, issue.774, p.25, 2013. ,
, Caisse Nationale d'Assurance Maladie. Caractéristiques et trajets de soins des insuffisants cardiaques du régime général. Points de repère, revue de l'assurance maladie n°38, août, issue.38, 2012.
, Participation à la conférence de presse du Groupe Insuffisance Cardiaque et Cardiomyopathies-2
, , p.16, 2017.
,
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Eur Heart J, vol.37, issue.27, pp.1765-1773, 1994. ,
, Effects of enalapril on mortality in severe congestive heart failure, N Engl J Med, vol.316, issue.23, pp.1429-1435, 1987.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, vol.325, issue.5, pp.293-302, 1991. ,
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials, Circulation, vol.110, issue.17, pp.2618-2626, 2004. ,
The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, vol.341, issue.10, pp.709-717, 1999. ,
,
, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, vol.364, issue.1, pp.11-21, 2011.
,
, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, vol.371, issue.11, pp.993-1004, 2014.
,
,
Multicentre randomised trial of a multidisciplinary intervention program in heart failure patients in French medical practice, EUROPEAN HEART JOURNAL, vol.20, pp.484-484, 2003. ,
, EHFS II): a survey on hospitalized acute heart failure patients: description of population, EuroHeart Failure Survey II, vol.27, issue.22, pp.2725-2736, 2006.
Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey, Eur J Heart Fail, vol.9, issue.12, pp.1205-1211, 2007. ,
Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure, Int J Cardiol, vol.175, issue.1, pp.83-89, 2014. ,
Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey, Eur J Heart Fail, vol.18, issue.5, pp.514-522, 2016. ,
Management of heart failure by general practitioners in France. Results of the study IMPROVEMENT of heart failure (IMPROVEMENT-HF). Arch Mal Coeur Vaiss, vol.95, pp.11-15, 2002. ,
Management of heart failure by French general practitioners in 2003, Arch Mal Coeur Vaiss, vol.97, issue.9, pp.833-839, 2004. ,
La grille communale de densité, 2018. ,
, Observatoire des Territoires, p.10, 2017.
,
,
, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, The Lancet, vol.376, issue.9744, pp.875-885, 2010.
,
HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure ,
Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey, Arch Cardiovasc Dis, vol.105, issue.6-7, pp.355-365, 2012. ,
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program, Am Heart J, vol.159, issue.5, pp.841-849, 2010. ,
Characteristics of heart failure patients using a Smartphone in the OFICSel cohort to develop a futur specific numeric application, 2018. ,
,
Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry, J Am Coll Cardiol, vol.72, issue.4, pp.351-366, 2018. ,
, GICC. plus d'un million de personnes atteintes d'insuffisance cardiaque en France
, , 2017.
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction, Cardiovasc Drugs Ther, vol.15, issue.1, pp.79-87, 2001. ,
Medical Inertia in the Optimization of Heart Failure Treatment after Discharge and its Relationship to Outcome, Health Care Curr Rev, vol.6, issue.221, p.2, 2018. ,
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med, vol.334, issue.21, pp.1349-1355, 1996. ,
Université de Bordeaux; 2014. 39. l'assurance maladie, Société Française de Cardiologie. retour à domicile après hospitalisation. suivi en ville après décompensation cardiaque, 2013. ,
,
Suivi à distance des patients en insuffisance cardiaque, Mt Cardio, vol.4, issue.2, pp.104-111, 2008. ,
,
, Groupe Insuffisance Cardiaque et Cardiomyopathies (GICC)-Paris
,